(Alliance News) - Renalytix PLC on Thursday confirmed that trading during the third quarter of its current financial year is in line with its expectations, and reported the firm has reached a key milestone in processed tests. Read More
(Alliance News) - Renalytix PLC on Tuesday backed its sales outlook as it reported a narrowed loss reflecting a marked drop in costs. Read More
(Alliance News) - Renalytix PLC on Monday said it is on track to meet financial expectations for financial 2025 and 2026 and it expects to report a slight increase in revenue in the first half. Read More
(Alliance News) - Renalytix PLC on Thursday said its new commercial strategy is working and that it is delivering growth from its Direct-to-Doctor sales force. Read More
(Alliance News) - Renalytix PLC on Tuesday announced a successful fund raise alongside a narrowed annual loss. Read More
(Alliance News) - Falling oil prices which knocked share prices of index heavyweights, BP and Shell, plus a sharp drop in BT, weighed on London's blue-chip index on Tuesday. Read More
Renalytix PLC - London-based in vitro diagnostics for kidney disease - Shares fall as Renalytix ends the formal sale process it launched back in March without an offer. Based on its discussions to date, the board doesn't think there is a "realistic prospect" of a takeover offer in the "near term". Renalytix says it is in talks with "key stakeholders" in the company about "a suitable capital structure and funding". Cash runway extends into the fourth quarter of this year based on its cash position of USD4.7 million on June 30. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Renalytix PLC on Tuesday said a possible suspension of trading in the company's American depositary shares on Nasdaq could impair its ability to raise capital. Read More
(Alliance News) - Renalytix PLC on Friday said Medicare had issued a final local coverage determination for its kidney testing kit, kidneyintelX.dkd. Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Tuesday and Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Renalytix PLC - London-based diagnostics company focused on the management and testing of kidney disease through its KidneyIntelX platform - Chief Business Officer Howard Doran has been appointed as president, effective April 30. He replaces Thomas McLain, who is stepping down as president on the same date after serving in the role since July 2019. Doran has been business chief since September last year. Read More
Renalytix PLC - London-based diagnostics company focused on the management and testing of kidney disease through its KidneyIntelX platform - Announces direct offer of shares at a purchase price equivalent to USD0.75 per NASDAQ American Depositary Share, or USD0.375 per common stock share, to DB Capital Partners Healthcare LP, an investor focused on innovative medical technology. Says the fundraise was conducted by way of a securities purchase agreement, consisting of an initial tranche of 2.7 million shares for USD1.0 million, and an optional subsequent tranche. If the optional tranche is exercised, Renalytix expects the total amount of financing to reach USD4 million. The price of USD0.375 per ordinary share represents a premium of roughly 4.1% to the company's closing price on Friday. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Renalytix PLC - London-based diagnostics company focused on its flagship KidneyIntelX prognostic for patients with kidney disease - Launches placing for around USD10 million, or GBP7.8 million. The placing involves the issue of around 39 million shares in the company at a price of 20 pence each. This represents a roughly 28% discount to the company's Monday closing price of 38.54 pence per share. Renalytix says that issuing more than 20.0 million shares will require shareholder approval, which the company intends to seek at a general meeting, the date and time of which has yet to be confirmed. Read More
Renalytix PLC - London-based diagnostics company, focused on prognosis services for patients with chronic kidney disease - Receives an unsolicited approach from a strategic acquiror which is evaluating a acquisition of the company's entire share capital. Renalytix describes the potential acquiror as a "large and well-capitalised publicly listed strategic diagnostics company". Renalytix has commenced a review of its options, including the sale of the company or its assets, and commenced a formal sale process. Renalytix says it may conclude that its interests are better served by other strategic options, including trading on AIM and Nasdaq as an independent entity, and therefore notes that there is no guarantee of the sale's completion. Read More